TCT-756 CHADS2 and CHA2DS2-VASc Scores in Atrial Fibrillation: Which Patients Actually Have Strokes?  by Malik, Rahul et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B307min in group 1 and 16.2  9.8 min in group 2). The rate of major cerebral
complications (fatal or non-fatalmajor stroke,minor stroke, PRIND, TIA
or death) was 10.1% in group 1 and 6.7% in group 2 (p¼0.042). After the
introduction of cerebral protection devices in April 2004, a signiﬁcant
reduction of the complication could be observed in all patients (11.1%
without and 6.5% with protection). With respect to the two groups
deﬁned above, reduction was signiﬁcant in group 1 (14.8% without and
7.1% with protection device [p¼0.003]) whereas in group 2 only a pos-
itive trend from 7.8% to 6,0% (p¼0.402) could be found.
CONCLUSIONS There are different peri-interventional complication
rates in pts undergoing CAS depending on the vessel treated. The
more complex anatomical situation at the origin of the left carotid
artery might result in a more frequent mobilization of intraluminal
plaque components from the aorta or the truncus brachiocephalicus.
The signiﬁcant reduction of cerebrovascular events when using ﬁlter
devices corroborates this hypothesis.
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BACKGROUND Instent- restenosis is a major issue after all intravascular
interventional treatments applying stents. We retrospectively analyzed
data from our center with respect to instent-restenosis rates in patients
who had undergone carotid artery stenting (CAS) at our department.
METHODS We retrospectively analyzed 1137 consecutive patients
(pts) with a mean age of 71.7  38.6 years who had undergone 1150
interventional procedures of the carotid arteries at our institution
between December 1997 and January 2015,. Post-interventional
routine follow-up with an ultrasound examination was scheduled at
one as well as six months after the procedure and after that on a yearly
basis. Signiﬁcant instent-restenosis was deﬁned as a lumen narrowing
>50% within the stent as assessed by Doppler velocities of more than
200 cm/second. Patients were divided into two groups with respect to
the stents used. 462 stenoses (40.2%) were treated with balloon-
expandable stents (group 1), whereas the remaining 688 stenoses
(59.8%) were treated with self-expandable stents (group 2).
RESULTS Long term follow-up with a mean duration of 38 months
showed an instent-restenoses rate of 6.8% (78 pts) for the entire cohort. In
group 1, instent-restenoses occurred in 54 pts (11.7%), in group 2, in 24 pts
(3.5%; p<0.001 for between group difference). Initial post-dilatation was
performed in 81 pts (17.5%) in group 1 but in 564 pts (82.0%) in group 2
(p<0.001). We found post-dilatation to signiﬁcantly decrease the in
instent-restenosis rate in group 1 (post-dilatation vs. no post-dilatation:
p¼0.037), but not in group 2 (post-dilatation vs. no post-dilatation:
p¼0.860). In group 2, no differencewas found between patientswhowere
treated with tapered or non-tapered stents (p¼0.114), respectively.
CONCLUSIONS Instent-restenoses >50% after CAS occurred infre-
quently during long term follow-up (6.8%) in our cohort. This state-
ment held true especially for those patients who had been treated
with self-expandable stents (3.5%). In patients who had been treated
with balloon-expandable stents, post-dilatation reduced instent-
restenoses signiﬁcantly. The shape of self-expandable stents did not
inﬂuence the instent-restenosis rate.
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BACKGROUND Recently transradial (TR) approach became a safe and
effective alternative of percutaneous carotid intervention (CI). Wereport the learning curve over 5 years in two high-volume interven-
tional centers during the transition from transfemoral (TF) to trans-
radial approach.
METHODS Between 2010 and 2014, 1541 patients underwent CI in our
centers. Clinical characteristics, radiation doses, volume of contrast
material, screening and procedure times of consecutive patients were
recorded prospectively in a register and restrospectively analyzed.
RESULTS Transradial approach was applied in 323 patients, mean age
was 686 years, 66% of them was male. The ratio of TR has grown
from 3 to 7, 25, 43 and 48% of the CIs, during the years respectively.
While the duration of the procedure (22.5 vs. 26 min, p¼0.016), the
ﬂuoroscopy time (7.4 vs. 9.7 min, p<0.001) and the applied contrast
material (90 vs. 128 ml, p<0.001) has signiﬁcantly decreased. How-
ever, these parameters were independent of the type of the aortic
arch. Conversion to TF was needed in 8.9% and remained stable. No
difference was observed in the incidence of minor or major vascular
events and hospitalization days, over the years.
CONCLUSIONS There was an initial learning curve for ﬂuoroscopy
time, contrast material. The change from TF to TR approach is
achievable in 5 years in high-volume centers.
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BACKGROUND Ischemic stroke is a dreaded complication feared by
patients (pts) with atrial ﬁbrillation (AF). The CHADS2 & CHA2DS2-
VASc scores are the gold standard for stroke risk stratiﬁcation in AF
pts; larger scores indicate higher risk of developing stroke and guide
anticoagulation strategy. This study evaluates CHADS2 and CHA2DS2-
VASc Scores in patients at the time of presentation with stroke.
METHODS We queried the institutional stroke data base in collaboration
with the stroke service to identify all pts with AF who presented with an
acute stroke. 86 consecutive pts with AF who presented with an acute
stroke to an urban teaching hospital between 2011-2014 were analyzed.
RESULTS 46 pts (53.5%) were women and 40 pts (46.5%) were men,
with mean age 77.311.2 years; 50 pts had persistent AF, 30 pts had
paroxysmal AF, and 6 pts had new onset AF. Hypertension and
obstructive sleep apnea were present in 93% and 4.7%, respectively.
Only 2 pts (1.2 %) had a CHADS2 score >5; the score was 0-1 in 8 pts
(9.3%). CHA2DS2-VASc score was low-intermediate risk (3-5) in 72.1%
and only 16.3% pts had a score > 5. The graphs show that the largest
incidence of stroke occurred in pts with low to intermediate risk
scores, not high risk. Warfarin was the prescribed anticoagulant in 31
pts, while only 3, 2, and 1 pts respectively were taking rivaroxaban,
dabigatran, and apixaban. The INR at the time of stroke for pts on
warfarin was therapeutic in 6 pts, sub-therapeutic in 20 pts, and su-
per-therapeutic in 5 pts. Reasons for the absence of anticoagulation in
the other 49 pts included non-compliance, bleeding history, high fall
risk, perioperative condition, physician decision, and patient refusal.
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VASc score is identiﬁed in most pts who present with stroke. The
implication of this data is that such patients remain at risk for stroke,
and raise questions about current therapeutic strategies.
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BACKGROUND The research is dedicated to the possibility of treat-
ment of patients with ischemic stroke by means of transcatheter
intracerebral surgery.
METHODS The research involved 746 patients aged 29-81 (mean age
74), predominantly with intracerebral atherosclerosis, after ischemic
stroke: males - 552 (73.99%), females - 194 (26.01%). The evaluation of
CDR, MMSE, IB was conducted; cerebral CT, MRI, MRA, scintigraphy
(SG), rheoencephalography (REG), cerebral MUGA: macrofocal strokes
were detected in 126 (16.89%) patients; midfocal strokes were detec-
ted in 362 (48.53%) patients; microfocal strokes were found in 258
(34.58%) patients. Transcatheter interventions were conducted in 452
(60.59%) patients – test group. To perform transcatheter revasculari-
zation of main intracerebral arteries, high-energy pulsed lasers were
used, for revascularization of distal intracerebral branches - contin-
uous low-energy lasers. Conservative treatment including desa-
gregate, anticoagulant, vasodilatory, antioxidant and nootropic
therapy was conducted in 294 (39.41%) patients - control group.
RESULTS Test Group. After the intervention, a good immediate
outcome was achieved in 443 (98.01%) patients due to the restoration
of patency and lumen of the affected vessels, as well as to the
collateral revascularization. 12 months after the treatment, the results
depended on the size of the ischemic lesion and the timing of the
intervention. Good clinical outcome (complete recovery of mental and
motor functions - IB 90-100) was obtained in 162 (35.84%) patients;
Satisfactory clinical outcome (incomplete recovery of mental and
motor functions - IB 75-85) - 212 (46.90%) patients; Relatively satis-
factory clinical outcome (partial restoration of mental and motor
functions - IB 60-70) - 78 (17.26%) patients; Relatively positive clinical
outcome (absence of negative dynamics with insigniﬁcant reduction
of mental and motor functions - IB below 60) was not obtained in any
case. Control Group. good clinical outcome was not obtained in any
case; satisfactory clinical outcome was obtained in 44 (14.97%) pa-
tients; relatively satisfactory clinical outcome - in 91 (30.95%) pa-
tients; relatively positive clinical outcome - in 159 (54.08%) patients.
CONCLUSIONS Transcatheter laser revascularization in the treatment
of ischemic stroke with intracerebral atherosclerotic lesions is more
effective than therapies. Restoration of intracerebral blood ﬂow can
signiﬁcantly reduce the level of mental, cognitive, motor disorders
and return patients to their active daily life.
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BACKGROUND Embolic protection in Carotid Artery Stenting (CAS)
has been shown to reduce the rate of major adverse cardiac and ce-
rebrovascular events (MACCE). We present the results of the WISEclinical study performed in high surgical risk patients using the novel
WIRION Embolic Protection System (EPS).
METHODS The WISE clinical study is a a multi-center, single arm
study performed on high surgical risk patients undergoing CAS using
the WIRION EPS. The primary safety endpoint was a composite of
Major Adverse Cardiac and Cerebrovascular Events (MACCE),
including Death, Stroke, and Myocardial Infarction (DSMI) occurring
within 30 days post-procedure. The primary end point was compared
to historical control from 5 previous US studies. WIRION is a distal EPS
that includes a rapid exchange, pre-crimped ﬁlter that can be used
with any commercially available 0.014” guide wire. The WIRION
remotely activated locking mechanism allows the stand-alone ﬁlter
unit to be positioned at any location on the wire along the vessel
without compromising wire performance. The WIRION Retrieval
Catheter includes a retractable tip allows smooth passage through the
stented area, minimize the risk of entanglement with the stent struts.
RESULTS One hundred and twenty (n¼120) high surgical risk patients,
mean age of 73.9 years were enrolled in the study. The treated lesions
average stenosis rate was 84% and 88% of the patients were asymp-
tomatic. WISE study primary endpoint was met at interim, following
recruitment of 120 out of the planned 240 patients. The 30-day com-
posite primary endpoint of MACCE as adjudicated by the CEC, was 3.3%
with 0% death. The obtained P value was 0.0008, less than the 0.0015
which is the performance goal of the study thus theWIRION systemmet
the primary end point. In 2 out of the 4 patients undergo MACCE the
event was non procedure nor device related. The following table pre-
sents the WISE primary endpoint results versus the historical control
data. The device success rate was 99.2% (119/120 patients) and angio-
graphic success was achieved in 97.5% (117 patients).Historical Control Group [%]Study Group
[%]ARCHeR 2 ARCHeR 3 BEACH MAVERIC CREATE AVG WISEAny MACCE 8.6 8.3 5.4 5.4 6.2 6.3 3.3Death 2.2 1.4 1.6 1 1.9 1.6 0Stroke 5.4 5.5 4.5 4.2 4.5 4.6 2.5Major 1.1 1.4 1.1 2.6 3.3 2.1 0Minor 4 3.5 2.2 1.2 0.5 1.9 1.6Myocardial Infraction 2.9 1.4 1.1 1.4 1 1.5 0.8EPS Accunet FilterWire GuardWire
(Medtronic)Spider WIRION(Abbott) (Boston Sci.) (ev3) (Gardia)CONCLUSIONS WISE study met its primary endpoint at interim,
demonstrating the safety and effectiveness of WIRION EPS in CAS of
high surgical risk patients when compared to the historical data of 4
other US marketed EPSs. It is simple to use and is highly rated by its
multiple users. The ability to cross the lesion over a guide wire of
choice and deploy the ﬁlter at the exact desired location creates a
unique, natural and appealing advantage for all indications.
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BACKGROUND New oral anticoagulants and the Watchman device
both represent alternatives to warfarin for stroke prophylaxis for atrial
ﬁbrillation. However, there are no studies comparing these new
treatment approaches. Thus, we performed a network meta-analysis
to indirectly compare Watchman and new oral anticoagulants (NOAC)
among atrial ﬁbrillation patients.
METHODS We performed a MEDLINE search for studies comparing
between warfarin and NOAC (dabigatran, rivaroxaban, apixaban and
edoxaban) or Watchman device in patients with atrial ﬁbrillation that
reported clinical outcomes. Mixed treatment comparison model gen-
eration was performed to directly and indirectly compare between
NOAC, warfarin and Watchman.
RESULTS A total of 14 studies with 246,005 patients were included in
the analysis, among which 122,811 were treated with warfarin, 119,602
were treated with NOAC and 732 had a Watchman device implanted.
